Finance

Lists
RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
US$ १५.३०
+३.०३%
(+०.४५) 1D
US$ १५.४०
+०.६५% (+०.१००)
After hours
Closed: सेप्टेम्बर ४, १६:००:०० GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RARE...
Open
US$ १५.४८
High
US$ १६.०८
Low
US$ १५.२३
Mkt. cap
१.५१ अरब
Avg. vol.
३०.८६ लाख
Volume
१.१५ करोड
52-wk high
US$ ३९.८९
52-wk low
US$ १३.८१
EPS
-US$ ५.८४
Beta
०.३२
Shares outstanding
९.८६ करोड
No. of employees
१ हजार
Open
US$ १५.४८
High
US$ १६.०८
Low
US$ १५.२३
Mkt. cap
१.५१ अरब
Avg. vol.
३०.८६ लाख
Volume
१.१५ करोड
52-wk high
US$ ३९.८९
52-wk low
US$ १३.८१
EPS
-US$ ५.८४
Beta
०.३२
Shares outstanding
९.८६ करोड
No. of employees
१ हजार
News stories
From web sources and news partners
Profile
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases. Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami. Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
About Ultragenyx Pharmaceutical Inc
CEOEmil Kakkis
Employees१.३७ हजार
Founded२०१०
HeadquartersNovato, क्यालिफोर्निया, संयुक्त राज्य अमेरिका
Sector-
Websiteultragenyx.com
Analyst ratings
Based on 19 analysts giving stock ratings to RARE in the past 3 months
Buy
Buy
9
Hold
10
Sell
0
12-month forecast
Based on 19 Wall Street analysts offering 12 month price targets for RARE in the last 3 months.
Highest
Current US$ १५.३०
US$ ६८.०० (+३४४.४४%)
Average
US$ २७.१७ (+७७.५८%)
Lowest
US$ १६.०० (+४.५८%)
Analyst
Recommendation
Action
Price target
Projected
Date
Sami Corwin
William Blair
Hold
Downgraded
-
-
09/05/2026
Salveen Richter
Goldman Sachs
Hold
Maintained
US$ १९.००
+२४.२%
09/04/2026
Eliana Merle
Barclays
Buy
Maintained
US$ ३२.००
+१०९.२%
09/03/2026
Maxwell Skor
Morgan Stanley
Hold
Downgraded
US$ १८.००
+१७.६%
09/03/2026
Tazeen Ahmad
Bank of America Securities
Hold
Downgraded
US$ २०.००
+३०.७%
09/03/2026
Maury Raycroft
Jefferies
Buy
Maintained
US$ २८.००
+८३%
09/03/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Maintained
US$ ३३.००
+११५.७%
09/03/2026
Laura Chico
Wedbush
Hold
Maintained
US$ २३.००
+५०.३%
09/03/2026
Luca Issi
RBC Capital
Hold
Downgraded
US$ १९.००
+२४.२%
09/03/2026
Whitney Ijem
Canaccord Genuity
Buy
Maintained
US$ ३७.००
+१४१.८%
09/03/2026
Yigal Nochomovitz
Citi
Buy
Maintained
US$ २८.००
+८३%
09/03/2026
Benjamin Burnett
Wells Fargo
Hold
Downgraded
US$ १८.००
+१७.६%
09/03/2026
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
US$ २५.००
+६३.४%
09/03/2026
Anupam Rama
J.P. Morgan
Hold
Downgraded
US$ ३६.००
+१३५.३%
09/03/2026
Jack Allen
Robert W. Baird
Hold
Downgraded
US$ १६.००
+४.६%
09/03/2026
Gavin Clark-Gartner
Evercore ISI
Hold
Downgraded
US$ १६.००
+४.६%
09/02/2026
Yaron Werber
TD Cowen
Buy
Reiterated
US$ १८.००
+१७.६%
09/03/2026
Unknown Analyst
Jefferies
Buy
Maintained
US$ ७७.००
+४०३.३%
08/21/2026
Unknown Analyst
Wedbush
Hold
Maintained
US$ ३०.००
+९६.१%
08/20/2026
Allison Bratzel
Piper Sandler
Buy
Maintained
US$ ६८.००
+३४४.४%
08/17/2026
Debjit Chattopadhyay
Guggenheim
Buy
Maintained
US$ ३५.००
+१२८.८%
08/03/2026
Joon Lee
Truist Financial
Buy
Maintained
US$ ७६.००
+३९६.७%
02/13/2026
Last report
२०२६ अगस्ट ४
Fiscal period
Q2 2026
EPS / Est. (USD)
-US$ ०.९० / -US$ १.००
+९.७४%beat
Revenue / Est. (USD)
२१.४० करोड / १८.३१ करोड
+१६.८९%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
१५.९९ करोड
२०.७३ करोड
१३.६० करोड
२१.४० करोड
Cost of goods sold
२४.४२ करोड
२३.२६ करोड
१८.९० करोड
२०.१० करोड
Cost of revenue
२४.४२ करोड
२३.२६ करोड
१८.९० करोड
२०.१० करोड
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
८.६६ करोड
८.७९ करोड
८.६० करोड
८.८० करोड
Operating expense
८.६६ करोड
८.७९ करोड
८.६० करोड
८.८० करोड
Total operating expenses
३३.०८ करोड
३२.०६ करोड
२७.५० करोड
२८.९० करोड
Operating income
-१७.०९ करोड
-११.३३ करोड
-१३.९० करोड
-७.५० करोड
Other non operating income
-१०.४३ लाख
-९.३४ लाख
-
१०.०० लाख
EBT including unusual items
-१७.९५ करोड
-१२.७७ करोड
-१८.४० करोड
-९.१० करोड
EBT excluding unusual items
-१८.०२ करोड
-१२.७२ करोड
-१५.४० करोड
-९.१० करोड
Income tax expense
८.७३ लाख
८.७० लाख
१०.०० लाख
१०.०० लाख
Effective tax rate
-०.४९%
-०.६८%
-०.५४%
-१.१०%
Other operating expenses
-
-
-
-
Net income
-१८.०४ करोड
-१२.८६ करोड
-१८.५० करोड
-९.२० करोड
Net profit margin
-११२.८१%
-६२.०२%
-१३६.०३%
-४२.९९%
Earnings per share
-१.८१
-१.२९
-१.५४
-०.९०
Interest and investment income
५८.६३ लाख
६५.१२ लाख
६०.०० लाख
५०.०० लाख
Interest expense
-१.४१ करोड
-१.९५ करोड
-२.१० करोड
-२.२० करोड
Net interest expenses
-८२.८५ लाख
-१.३० करोड
-१.५० करोड
-१.७० करोड
Depreciation and amortization charges
-
-
-
-
EBITDA
-१६.२३ करोड
-१०.४५ करोड
-१३.१० करोड
-६.७० करोड
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google एपहरू